Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DNTH vs NTLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DNTH Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–2 Matrix Metrics)

DNTH Overall Winner 6-Pillar Tally: DNTH 4 – 2 NTLA Matrix Metrics: DNTH 5 – 2 NTLA

As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DNTH carries a Unified Composite Score of 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin).

  • Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. -826.0% operating margin) and revenue trajectory (+205.6% vs. -48.0% YoY).
  • Technical & Structure Timing Caution: DNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 55.0); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DNTH vs NTLA
DNTH NASDAQ Head-to-Head Winner
Dianthus Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$88.58
-3.52% 1D
Market Cap $5.2B
TTM Revenue $2.7M
Forward P/E N/M
Beta / 30D Vol 1.03β · 41% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 8.0 Fund 43.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.0 · SMA20: $83.96 · SMA50: $88.06
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $11.58 · SMA50: $11.86

6-Pillar Scorecard Institutional Category Breakdown (DNTH 4 – 2 NTLA)

Columns: Metric · DNTH · NTLA
1. Valuation Multiples NTLA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 29.1x
2. Growth & Scale DNTH
Revenue Growth (YoY) +205.6% -48.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.7M $53M
Market Cap $5.2B $1.5B
3. Profitability & Quality DNTH
Gross Margin 100.0% N/A
Operating Margin -8683.9% -826.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -22.6% -62.6%
4. Balance Sheet & Cash Flow DNTH
Cash Generation (TTM) -$176M -$358M
Cash Flow Margin N/A N/A
Net Cash / Leverage $54M Net Cash $74M Net Debt (0.38x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DNTH
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 83.5% (7th %ile) 101.3% (78th %ile)
Put/Call OI Skew N/A 0.42x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DNTH (5) vs NTLA (2)
Institutional Metric DNTH NTLA Criterion Row Edge
Market Capitalization
Scale
$5.2B $1.5B Larger Scale DNTH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+205.6% -48.0% Higher Growth DNTH
Operating Margin (TTM)
Profitability
-8683.9% -826.0% Higher Margin NTLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-22.6% -62.6% Higher ROE DNTH
52-Week Range Position
Momentum
65% ($34–$118) 20% ($8–$18) Stronger Trend DNTH
Beta / 30D Volatility
Risk Regime
1.03β · 41% Vol 2.30β · 87% Vol Lower Realized Risk DNTH
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 50.7 / 100 (HOLD) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$2.7M $53M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 29.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($54M Net Cash) -$358M ($74M Net Debt (0.38x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DNTH +35.3 pp
DNTH: +22.87% · NTLA: -12.43%
3M Horizon NTLA +9.55 pp
DNTH: -23.34% · NTLA: -13.79%
6M Horizon DNTH +27.15 pp
DNTH: +5.95% · NTLA: -21.2%
1Y Horizon DNTH +134.17 pp
DNTH: +149.51% · NTLA: +15.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DNTH Revenue NTLA Revenue DNTH Op. Margin NTLA Op. Margin Margin Leader
FY2018 N/A $30M N/A -298.6% NTLA
FY2019 N/A $40M N/A -246.8% NTLA
FY2020 N/A $60M N/A -235.5% NTLA
FY2021 N/A $30M N/A -810.4% NTLA
FY2022 N/A $50M N/A -879.0% NTLA
FY2023 $0M $40M -1704.7% -1420.5% NTLA
FY2024 $10M $60M -1633.7% -923.1% NTLA
FY2025 $0M $70M -8739.3% -651.7% NTLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DNTH CONSOLIDATION
149d in phase · OBV ACCUMULATION
Current IV 83.5%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DNTH Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.2B market capitalization and -8683.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ DNTH vs NTLA Key Questions & Quantitative Answers

As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DNTH carries a Unified Composite Score of 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. -826.0% operating margin) and revenue trajectory (+205.6% vs. -48.0% YoY). Technical & Structure Timing Caution: DNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 55.0); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DNTH leads the Growth & Scale pillar: DNTH posts +205.6% YoY revenue growth and +0.0% YoY earnings growth on $2.7M TTM revenue (100.0% gross margin, -8683.9% operating margin), compared with NTLA at -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DNTH cumulative revenue shifted N/A while NTLA shifted +133.3%. In operating R&D and SG&A reinvestment, DNTH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NTLA.

NTLA screens cheaper on headline valuation multiples. DNTH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DNTH (-22.6% ROE) versus NTLA (-62.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DNTH carries 83.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.03β · 41% Vol realized risk). By comparison, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.